Prothrombinase catalyzes thrombin formation by the ordered cleavage of two peptide bonds in prothrombin. Although these bonds are likely Ϸ36 Å apart, sequential cleavage of prothrombin at Arg-320 to produce meizothrombin, followed by its cleavage at Arg-271, are both accomplished by equivalent exosite interactions that tether each substrate to the enzyme and facilitate presentation of the scissile bond to the active site of the catalyst. We show that impairing the conformational transition from zymogen to active proteinase that accompanies the formation of meizothrombin has no effect on initial cleavage at Arg-320 but inhibits subsequent cleavage at Arg-271. Full thermodynamic rescue of this defective mutant was achieved by stabilizing the proteinase-like conformation of the intermediate with a reversible, active sitespecific inhibitor. Irreversible stabilization of intact prothrombin in a proteinase-like state, even without prior cleavage at Arg-320, also enhanced cleavage at Arg-271. Our results indicate that the sequential presentation and cleavage of the two scissile bonds in prothrombin activation is accomplished by substrate bound either in the zymogen or proteinase conformations. The ordered cleavage of prothrombin by prothrombinase is driven by ratcheting of the substrate from the zymogen to the proteinase-like states.
T hrombin (IIa) is produced in a pivotal reaction of the blood coagulation cascade by specific proteolysis of prothrombin at two sites (1) . The membrane-assembled prothrombinase complex is considered the physiologically relevant catalyst for this reaction (1, 2) . Prothrombinase acts on the two scissile bonds through sequential cleavage reactions in an apparently ordered fashion. Provided that membrane binding by prothrombin is not compromised, prothrombin is cleaved after Arg-320 to yield meizothrombin ¶ (mIIa) as an intermediate, followed by subsequent cleavage at Arg-271 to produce IIa (3, 4) . The molecular bases for these findings remain obscure.
Because both cleavage sites in the zymogen appear accessible to proteolysis, prothrombin can be converted to thrombin by two possible cleavage pathways (3) (4) (5) (6) . Substrates for each of the four possible half-reactions in prothrombin activation bind prothrombinase in a mutually exclusive fashion and with equivalent affinity (4, 7) . Three of the four possible reactions exhibit identical catalytic efficiencies, whereas cleavage at Arg-271 in intact prothrombin proceeds with a V max that is Ϸ30-fold lower (4) . These findings establish the quantitative basis for preferential cleavage at Arg-320 over Arg-271 in intact prothrombin and the largely ordered cleavage pathway that ensues (4) . They fail, however, to provide an explanation for why a difference in V max , and not affinity, drives selective recognition of the Arg-320 bond in intact prothrombin or why initial cleavage at Arg-320 greatly enhances the V max for subsequent cleavage at Arg-271 without also affecting substrate affinity.
Substrate recognition in each of the four possible halfreactions is accomplished by an initial, active site-independent interaction with an extended surface (exosite) on prothrombinase, followed by active site engagement by the substrate and cleavage (8) . Exosite binding is the principal determinant of substrate affinity, whereas the subsequent active site docking step contributes to the V max (8) . Cleavage of two scissile bonds is likely accomplished by a single exosite interaction that tethers the substrate to prothrombinase and presents structures flanking each cleavage site to the catalyst for active site docking (9) . Because the two scissile bonds are expected to be separated by Ϸ36 Å in intact prothrombin, geometric constraints arising from exosite tethering might be expected to both facilitate and restrict active site docking of elements flanking each scissile bond with the active site of prothrombinase (4) . Ordered cleavage and bond selectivity associated with differences in V max could result from presentation constraints associated with substrate bound in one of two configurations to prothrombinase (4, 8) .
Initial cleavage at Arg-320 converts prothrombin, the zymogen, to the serine proteinase mIIa (10) . Abundant x-ray crystallographic evidence developed with members of the S1 family of serine proteinases exhibiting a chymotrypsin fold has established the mechanism(s) by which cleavage at this site results in conformational transitions and the conversion of the zymogen to the proteinase (11) (12) (13) (14) . The zymogen and proteinase could represent two distinct substrate conformations that are relevant to the action of prothrombinase on prothrombin. We have investigated the role of the zymogen to proteinase transition in determining the ordered presentation and cleavage of the two scissile bonds required for the conversion of prothrombin to thrombin.
Experimental Procedures
Reagents. The inhibitors D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone (FPR-CH 2 Cl, Calbiochem) and dansyl-Larginine N- (3-ethyl-1,5-pentanediyl) amide (DAPA, Hematologic Technologies, Essex, VT) were obtained from the indicated sources. The peptidyl substrate, H-D-phenylalanyl-L-pipecolyl-L-arginine-P-nitroanilide (S2238), was from Chromogenix. Small unilamellar phospholipid vesicles (PCPS) composed of 75% (wt͞wt) hen egg L-␣-phosphatidylcholine and 25% (wt͞wt) porcine brain L-␣-phosphatidylserine (Avanti Polar Lipids) were Abbreviations: II, prothrombin; mIIa, meizothrombin; IIa, thrombin; IITAT, II containing Thr-Ala-Thr after Arg-320; IIQ320, II containing Gln in place of Arg-320; IIQ155,Q284, a thrombin resistant variant of II containing Gln in place of Arg-155 and Arg-284; IIWT, recombinant wild-type human II; DAPA, dansyl-L-arginine N- (3-ethyl-1,5-pentanediyl) amide; FPR-CH2Cl, D-phenylalanyl-L-prolyl-L-arginine chloromethyl ketone; FPR-IIQ320, IIQ320 covalently modified with FPR-CH2Cl after conformational activation; Met-SC1-325-His-6, residues 1-325 of staphylocoagulase containing an additional Met at the NH2-terminus and a His tag at the COOH terminus; PCPS, small unilamellar phospholipid vesicles composed of 75% (wt͞wt) hen egg L-␣-phosphatidylcholine and 25% (wt͞wt) porcine brain L-␣-phosphatidylserine. § To whom correspondence should be addressed. E-mail: skrishna@mail.med.upenn.edu. ¶ Residues in prothrombin are consecutively numbered starting at the NH2-terminus of mature human prothrombin. prepared and characterized as described in ref. 15 . Factors Xa and Va were prepared from factors X and V purified from human plasma and quality controlled as described in refs. 3, 4, and 16. A fragment comprising residues 1-325 of staphylocoagulase containing an additional Met at the NH 2 terminus and a His tag at fused to the COOH terminus (Met-SC 1-325 -His-6) was prepared by modification of an expression construct described in ref. 13 . Deletion of a stop codon allowed translation of an additional Lys-Leu-Ala-Ala-Ala-Leu-Glu-His-6 sequence at the COOH terminus. Met-SC 1-325 -His-6 was expressed as described in ref. 13 The Gateway system (Invitrogen) was used to transfer the cassette encoding the prothrombin variants to an adapted pCDNA 3.1 (ϩ) vector as described in ref. 4 , and the integrity of each cassette was established by DNA sequencing. Transfection of HEK293 cells, selection of stable cell lines, large-scale expression, and purification of II TAT and II Q155,Q284 were performed as described in ref. 4 . NH 2 -terminal sequencing and quantitative determination of ␥-carboxyglutamic acid content, as described in refs. 4 and 19, established a correctly processed NH 2 -terminal sequence and a full complement of ␥-carboxyglutamic acid residues for each prothrombin variant (data not shown).
Preparation of FPR-IIQ320. Conformational activation of II Q320 and its covalent inactivation with FPR-CH 2 Cl was accomplished by the addition of 43 M Met-SC 1-325 -His-6 to a reaction mixture equilibrated at 25°C containing 25 M II Q320 and 250 M FPR-CH 2 Cl in 140 mM Hepes͞76 mM NaCl͞11% (vol/vol) glycerol, pH 7.8. Conformationally activated II Q320 was Ϸ99% inhibited after 10 min, as measured by initial rates of S2238 hydrolysis. The incubation was continued for an additional 75 min, and the Met-SC 1-325 -His-6⅐FPR-II Q320 complex was captured by application to a column of Ni 2ϩ -iminodiacetic acidSepharose equilibrated in 50 mM Hepes͞400 mM NaCl͞50 mM imidazole͞10 M FPR-CH 2 Cl, pH 7.4. II Q320 covalently modified with FPR-CH 2 Cl after conformational activation (FPR-II Q320 ) was eluted with 50 mM Hepes͞125 mM NaCl͞3 M NaSCN, pH 7.4, dialyzed against 50 mM Hepes͞125 mM NaCl, pH 7.4, and separated from trace amounts of Met-SC 1-325 -His-6͞FPR-II Q320 complex by chromatography on tandem Superdex 200 HR 10͞30 columns (Amersham Pharmacia) equilibrated in the same buffer. FPR-II Q320 free of Met-SC 1-325 -His-6, eluting in the second of two peaks, was pooled, snap-frozen, and stored at Ϫ70°C. Residual uninhibited II Q320 was estimated at Ϸ0.5%, as determined from the rate of S2238 hydrolysis after incubation of 100 nM FPR-II Q320 with a staphylocoagulase fragment comprising residues 1-325 (250 nM) for 20 min at 25°C. A control substrate was prepared by treating II Q320 with 3 M NaSCN for 2 h at room temperature, followed by gel filtration into 50 mM Hepes͞0.11 M NaCl͞5 mM Ca 2ϩ ͞0.1% (wt/vol) PEG 8000, pH 7.4 and dialysis into 50 mM Hepes͞125 mM NaCl, pH 7.4 before freezing. Both II Q320 and FPR-II Q320 were thawed and diluted into 35 mM Hepes͞0.15 M NaCl͞2 mM Ca 2ϩ ͞0.1% (wt/vol) PEG 8000, pH 7.4 before use. Binding of DAPA to Thrombin Variants. Front face fluorescence measurements were performed in a plate reader (SpectraMax Gemini, Molecular Devices) by using black polystyrene plates (no. 3650, Corning). Reaction mixtures (100 l) prepared in assay buffer contained increasing concentrations of DAPA (24 concentrations, 0-100 M) with no addition, 0.5 M IIa, or 0.5 M IIa TAT . Fluorescence intensity was determined by integrating emission spectra between 510 and 530 nm at 25°C by using EX ϭ 280 nm with a 495-nm long-pass filter in the emission beam. Subtraction of the intensity measured with DAPA alone yielded the fluorescence change associated with the binding of DAPA to IIa or IIa TAT . Fluorescence data were analyzed as described in ref. 7 to infer the equilibrium dissociation constant.
Kinetics of Bond Cleavage in Prothrombin

Results
Activation-Defective Variant of Prothrombin. Initial cleavage of prothrombin at Arg-320 reveals a new NH 2 -terminal sequence (Ile-Val-Glu) that is essential for the formation of an internal salt bridge. Salt bridge formation induces conformational changes in the proteinase domain and maturation of the active serine proteinase (11, 13, 20) . We prepared a recombinant prothrombin derivative (II TAT ) in which the Ile-Val-Glu sequence was replaced with Thr-Ala-Thr, normally found after the Arg-271 cleavage site. The intent was to produce a prothrombin variant that could be cleaved normally but with impaired ability to undergo the conformational transition to active proteinase after cleavage at Arg-320. Accordingly, II TAT could be fully converted to IIa TAT ʈ after prolonged digestion with prothrombinase (see below). Although correct cleavage at Arg-320 was verified by NH 2 -terminal sequencing, purified IIa TAT exhibited only Ϸ0.2% of the specific activity of wild-type IIa as determined by initial velocity measurements with 100 M S2238 (data not shown).
Kinetics of Prothrombin Cleavage. Cleavage of II WT by prothrombinase yielded bands established to arise from the sequential cleavage at Arg-320, yielding mIIa as the sole intermediate, followed by cleavage at Arg-271 to produce IIa (4). Prothrombin disappearance was accompanied by the transient appearance of ʈ mIIaTAT and IIaTAT refer to mIIa and IIa produced from IITAT.
F1.2-A, uniquely associated with mIIa formation, followed by the delayed appearance of F1.2 and A chain of IIa, denoting IIa production (Fig. 1A) . Cleavage of II WT has been established to be qualitatively and quantitatively indistinguishable from the cleavage of prothrombin isolated from plasma (4). An equivalent banding pattern and key diagnostic features of the reaction profile observed with II TAT (Fig. 1B) implicated the same order of bond cleavage in this variant. However, although II TAT disappeared in a way that was comparable with II WT , the band arising from mIIa TAT produced after initial cleavage at Arg-320 was more intense and persisted throughout the time course. Bands arising from IIa TAT produced by the second cleavage reaction at Arg-271 appeared more slowly (Fig. 1B) .
Quantitative densitometry yielded a reaction profile for II WT cleavage that was consistent with the sequential conversion of II WT to mIIa, followed by its cleavage at Arg-271, to produce IIa ( Fig. 2A) . Initial rates of consumption of II WT and II TAT , resulting from cleavage at Arg-320, were comparable and differed only by Ϸ15% (Fig. 2) . The lower extent of II TAT consumption most likely reflects the results of product inhibition by the accumulating intermediate. For either substrate, mIIa was produced at the same initial rate. However, mIIa TAT accumulated to a greater extent and decayed slowly, with significant amounts evident even after 30 min, whereas IIa TAT was produced at a slower rate (Fig. 2B) . Additional data points extending to 120 min established quantitative conversion of II TAT to IIa TAT (data not shown).
Studies of II WT cleavage require the use of DAPA, a tightbinding inhibitor of IIa and mIIa, to prevent feedback cleavages in the substrate and intermediate (Figs. 1 A and 2 A) . DAPA was not present in studies with II TAT (Figs. 1B and 2B) . Differences in the cleavage of II WT and II TAT could reflect an unexpected effect of DAPA unrelated to the sequence after the Arg-320 cleavage site. This possibility was eliminated by the results of studies with and without DAPA by using II Q155,Q284 , a thrombinresistant variant (Fig. 3) . The reaction profile for II Q155,Q284 cleavage by prothrombinase was comparable with that observed for the cleavage of II WT both in the presence and absence of 60 M DAPA (Fig. 3) .
The data indicate that mutation of the residues after the Arg-320 cleavage site and the associated impairment in proteinase formation has minimal impact on the first cleavage reaction at Arg-320 but produces a distant effect on subsequent cleavage at Arg-271. Integration of the area under the progress curve for mIIa formation (extending to 120 min) suggests that the second cleavage reaction is Ϸ20-fold slower in II TAT than in II WT or in II Q155,Q284 .
Rescue of IITAT Cleavage by DAPA. In contrast to the findings with II Q155,Q284 , DAPA significantly altered product profiles of II TAT cleavage without detectably influencing bond cleavage order. DAPA had a minor effect on II TAT consumption (Fig. 4) . Increasing concentrations of DAPA, as high as 300 M, did not significantly affect the initial rate of mIIa TAT formation but decreased the amplitude of mIIa TAT production and increased the rate of IIa TAT formation (Fig. 4) . At saturating concentrations of DAPA, progress curves for mIIa TAT and IIa TAT resembled those obtained in the activation of II WT . The observations indicate that DAPA has a minimal effect on the initial cleavage of II TAT at Arg-320 but can rescue defective cleavage at Arg-271. This rate-enhancing effect of DAPA on Arg-271 cleavage is specific to the action of prothrombinase on II TAT .
Effects of DAPA were assessed by integrating areas under the progress curves for mIIa formation and its disappearance for the different prothrombin variants (Fig. 5) . Normalized areas obtained in the activation of II WT or II Q155,Q284 were identical and were independent of DAPA varied between 0 and 300 M for II Q155,Q284 or 20 and 300 M for II WT . In the case of II TAT , the integrated area (obtained by integration to 120 min) was Ϸ20-fold higher in the absence of DAPA and decreased saturably to values observed with II WT (Fig. 5) . Thus, a defective second half-reaction in II TAT cleavage is fully rectified by high concentrations of DAPA with a half-maximal effect at Ϸ20 M.
Although DAPA is established to act as a tight-binding, active site-directed inhibitor of IIa and mIIa (K d Ϸ 1 nM) (21) , the data imply a far weaker interaction between DAPA and mIIa TAT or IIa TAT. Fluorescence studies assessing the binding of DAPA to IIa WT were consistent with a nanomolar equilibrium dissociation constant (data not shown). Although the amplitude of the fluorescence change observed with IIa TAT and saturating concentrations of DAPA was comparable with that observed with IIa WT , DAPA bound weakly to purified IIa TAT with K d ϭ 31.7 Ϯ 2.3 M (data not shown). This dissociation constant is in agreement with the concentration of DAPA required to observe 50% rescue of II TAT cleavage (Fig. 5) .
One interpretation of the results is that the full rescue of Arg-271 cleavage in II TAT by high concentrations of DAPA arises from its weak interaction with mIIa TAT and the thermodynamic stabilization of a proteinase-like state in an otherwise zymogen-like mIIa-TAT species produced after the initial cleavage at Arg-320. This interpretation implies that effective presentation of structures flanking the Arg-271 site to the active site of prothrombinase requires a substrate in a proteinase-like configuration.
Stabilization of the Uncleaved Zymogen in a Proteinase-Like State.
Prior work with a prothrombin variant (II Q320 ) containing a single cleavable site at Arg-271 has established that the Arg-271 site in the intact zymogen is cleaved slowly by prothrombinase (4) . In agreement, analysis by SDS͞PAGE and quantitative densitometry showed slow cleavage at Arg-271 in II Q320 (Fig. 6) . FPR-II Q320 was produced by conformational activation of II Q320 with Met-SC 1-325 -His-6, covalent inactivation of the complex with FPR-CH 2 Cl, followed by dissociation and separation from Met-SC 1-325 -His-6. FPR-II Q320 is an uncleaved prothrombin an- alog that is expected to be stabilized in a more proteinase-like state by the inhibitor covalently bound to the active site. Cleavage at Arg-271 in FPR-II Q320 by prothrombinase was enhanced Ϸ12-fold in comparison with cleavage at the same site in II Q320 (Fig. 6) . Thus, stabilization of the substrate in a proteinase-like state, even without cleavage at Arg-320, enhances presentation and cleavage at Arg-271.
Discussion
Our observations, along with the mechanisms established for substrate recognition by prothrombinase (8) , are consistent with the interpretations outlined in Scheme 1. Exosite-dependent tethering of the substrate to prothrombinase in either the zymogen or the proteinase configurations is proposed to govern presentation of the individual cleavage sites for docking to the active site of the catalyst and cleavage (Scheme 1). Active site docking of the Arg-320 site is facilitated when the substrate is bound in the zymogen configuration, whereas effective presentation of the Arg-271 site requires that the substrate is bound in the proteinase configuration after initial cleavage at Arg-320. These ideas provide an explanation, at the molecular level, for bond selectivity and the largely ordered action of prothrombinase on the two spatially distinct cleavage sites in prothrombin.
Selective impairment of the second cleavage reaction in the activation of II TAT is proposed to reflect the suboptimal presentation of the Arg-271 site because of the zymogen-like configuration of mIIa TAT despite its prior cleavage at Arg-320 (Scheme 1). Conversely, forcing the zymogen to adopt a proteinase-like configuration yields enhanced presentation and cleavage at Arg-271 even without prior cleavage at Arg-320 (Scheme 1). Thus, the conformational transition of the substrate between zymogen and proteinase states plays a role in regulating the action of prothrombinase on the two cleavage sites in the protein substrate.
The structural basis for the conversion of zymogen to proteinase in the chymotrypsin-like serine proteinases fold has been established with numerous x-ray structures, including those for derivatives of II, mIIa, and IIa (10) (11) (12) (13) (14) 22) . The Ile-Val-Glu NH 2 terminus generated after cleavage at Arg-320 inserts into the NH 2 -terminal binding cleft in the catalytic domain and yields a salt bridge between Ile-321 (Ile C16 )** and Asp C194 . Salt bridge formation triggers conformational changes in the so-called activation domains (11-14, 23, 24) . These changes are associated with the formation of the substrate binding pocket and the oxyanion hole required for catalysis (11) (12) (13) (14) 22) . In the case of mIIa, these conformational changes could also be transmitted to the other domains that remain covalently attached (25) . Because **Residues in the proteinase domain, numbered according to the homologous residues in chymotrypsinogen (22) , are denoted by a C preceding the residue number. formation of the internal salt bridge depends on the NH 2 -terminal sequence produced after cleavage at Arg-320, some or all of these linked changes are likely disrupted in mIIa TAT (11, 24) . It is not possible to discern whether impaired cleavage at Arg-271 in mIIa TAT , which we have ascribed to its zymogen-like nature, arises from all or a subset of the linked conformational changes associated with the zymogen to proteinase transition. Full and specific rescue of the defect in II TAT cleavage by high concentrations of DAPA indicates that this active site-directed ligand somehow rectifies impaired docking of the Arg-271 cleavage site with the active site of prothrombinase in the otherwise zymogen-like mIIa TAT (Scheme 1). Ligands that bind with high affinity to the proteinase are established to enhance the ability of the zymogen to adopt a proteinase-like configuration (13, 20, 23). Our findings are consistent with two possible interpretations. DAPA could bind weakly (K d Ϸ 30 M) to the zymogen-like mIIa TAT and overcome a kinetic and͞or thermodynamic barrier in its conversion to the proteinase-like state. Alternatively, DAPA could act by selectively binding and favoring the proteinase in an equilibrium between zymogen-like and proteinase-like forms of mIIa TAT in which the zymogen-like state is highly favored.
Effectively ordered cleavage of prothrombin by prothrombinase arises because Arg-271 in intact prothrombin is cleaved with a V max that is Ϸ30-fold lower than for cleavage at Arg-320, and prior cleavage at Arg-320 increases the V max for cleavage at Arg-271 by a factor of Ϸ30 (4). Provided the ideas outlined in Scheme 1 can fully explain the differential recognition of the two sites in prothrombin, blocking the conformational transition to proteinase is expected to maximally yield a Ϸ30-fold slower rate of cleavage at Arg-271, even after cleavage at Arg-320. Complete stabilization of the zymogen in the proteinase state is expected to maximally yield a Ϸ30-fold enhancement in cleavage at Arg-271, even without prior cleavage at Arg-320. These boundary conditions, established by the kinetic constants measured for the individual cleavage reactions, are generally consistent with the magnitude of effects we have observed. The somewhat smaller enhancement (Ϸ12-fold) observed in Arg-271 cleavage in FPR-II Q320 could reflect the possibility that this derivative has not been completely driven to a proteinase-like state. Nevertheless, taken together, the results illustrate that it is not cleavage at Arg-320 per se but the ensuing conformational change that facilitates subsequent cleavage at Arg-271.
Our findings now provide a comprehensive explanation for a range of kinetic findings and an explanation for how ordered cleavage of prothrombin is achieved. Ratcheting of the substrate from the zymogen to proteinase conformations drives the sequential presentation of the two cleavage sites to the active site of the catalyst leading to the ordered action of prothrombinase on prothrombin. These concepts may also have bearing on the mechanisms underlying the ordered action of proteinases at multiple sites in their protein substrates in coagulation and in other areas of biology.
